Fed’s Powell opens door to potential rate cuts at Jackson Hole
Applied Therapeutics Inc (NASDAQ:APLT) stock has plummeted to a 52-week low, reaching a price level of just $0.49. The micro-cap biotech company, now valued at $57.13 million, shows high volatility with a beta of 1.88. According to InvestingPro analysis, the stock appears undervalued at current levels. This significant drop reflects a stark contrast to the company’s performance over the past year, with the 1-year change data revealing a precipitous decline of -92.88%. Investors have watched the stock’s value erode steadily, culminating in this latest low point, which has raised concerns about the company’s future prospects and overall market sentiment towards the biopharmaceutical firm. Despite the decline, analyst price targets range from $1.50 to $13, with the next earnings report due March 14. InvestingPro subscribers can access 13 additional key insights and a comprehensive Pro Research Report for deeper analysis of APLT’s financial health and future potential.
In other recent news, Applied Digital Corporation reported fiscal second-quarter results that exceeded analyst expectations. The company achieved adjusted earnings per share of -$0.06, surpassing the anticipated -$0.14, and revenue reached $63.9 million, slightly above the forecasted $63.39 million. A significant contributor to this growth was the Cloud Services segment, which saw a 523% year-over-year increase in revenue, totaling $27.7 million. Meanwhile, the Data Center Hosting business generated $36.2 million in revenue. Applied Digital also announced a $5 billion perpetual preferred equity financing facility with Macquarie Asset Management to bolster its high-performance computing business.
In other developments, Applied Therapeutics, Inc. received a notification from the Nasdaq Stock Market regarding non-compliance with the minimum bid price requirement. The company has been given until August 6, 2025, to regain compliance by maintaining a closing bid price of at least $1.00 per share for ten consecutive business days. If unsuccessful, Applied Therapeutics may seek an additional 180-day extension by transferring its listing to the Nasdaq Capital Market. The company’s executive team is currently evaluating options to address this issue, although no specific course of action has been decided.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.